Pfizer-BioNTech vaccine not troubled by variants so far, says CEO


Sumary of Pfizer-BioNTech vaccine not troubled by variants so far, says CEO:

  • One of the people behind the Pfizer-BioNTech COVID-19 vaccine says he has yet to see any evidence that emerging variants of the disease have found a way to defeat it..
  • To address the second concern, BioNTech’s team of researchers run tests on the vaccine’s effectiveness against individual variants..
  • While Sahin said he is confident his vaccine will deal with existing variants, he said his company is constantly monitoring its effectiveness on new variants “to be on the safe side.”.
  • “And therefore, any decision for taking the vaccine should be aligned with the physician based on an analysis of risk-benefit.”.
  • As concerns about the risk of blood clots associated with the AstraZeneca-Oxford vaccine have grown, many have asked whether those who have had a single shot of the AstraZeneca-Oxford product can take the Pfizer-BioNTech vaccine as their second shot…

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.